Amyris (AMRS) – Get Report shares soared Friday after the biotech company announced promising in vivo results for a study of its licensed RNA vaccine for COVID through intranasal delivery.
The vaccine is being developed in collaboration with the Infectious Disease Research Institute, Amyris said.
Amyris recently traded at $13.67, up 13%.
“Current mRNA vaccine technologies are providing limited immunity protection for the upper respiratory system,” Amyris said. “As a result, vaccinated people may experience viral replication....More>>>